A Study of the Safety and Efficacy of Venetoclax for Patients With Chronic Lymphocytic Leukemia (CLL) Used in Routine Clinical Practice

2019 ◽  
Author(s):  
Keyword(s):  
Clinical Practice ◽  
Chronic Lymphocytic Leukemia ◽  
Routine Clinical Practice ◽  
Lymphocytic Leukemia ◽  
Safety And Efficacy

scholarly journals The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice

2020 ◽  
Vol 9 (10) ◽  
pp. 3390-3399 ◽  
Author(s):  
Sameer A. Parikh ◽  
Sara J. Achenbach ◽  
Timothy G. Call ◽  
Kari G. Rabe ◽  
Wei Ding ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Chronic Lymphocytic Leukemia ◽  
Routine Clinical Practice ◽  
Lymphocytic Leukemia ◽  
Dose Modification ◽  
The Impact

scholarly journals Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia

2021 ◽  
Author(s):  
Jing-Zhou Hou ◽  
Kellie Ryan ◽  
Senxi Du ◽  
Bruno Fang ◽  
Stanley Marks ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Chronic Lymphocytic Leukemia ◽  
Adverse Events ◽  
Dose Reduction ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Routine Clinical Practice ◽  
Lymphocytic Leukemia ◽  
First Line ◽  
Dose Reductions

Aim: A retrospective chart review of ibrutinib-treated patients with chronic lymphocytic leukemia (CLL) was conducted. Patients & methods: Adults with CLL who initiated ibrutinib were followed for ≥6 months (n = 180). Results: Twenty-five percent of first-line ibrutinib patients experienced ≥1 dose reduction, mainly due to adverse events (AEs; 79%). Treatment discontinuations and dose holds occurred in 20 and 34% of patients, respectively, most commonly due to AEs (73 and 74%). Approximately one-quarter of relapsed/refractory ibrutinib patients experienced ≥1 dose reduction, mainly due to AEs (88%). Treatment discontinuation and dose holds occurred in 40% of patients (58 and 76% due to AEs, respectively). Conclusion: Dose reductions, holds and discontinuations were frequent in patients with CLL receiving ibrutinib in routine clinical practice.

scholarly journals Monoclonal B-cell lymphocytosis: a brief review for general clinicians

2011 ◽  
Vol 129 (3) ◽  
pp. 171-175 ◽  
Author(s):  
Daniel Mazza Matos ◽  
Roberto Passetto Falcão
Keyword(s):  
Clinical Practice ◽  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Medical Condition ◽  
Routine Clinical Practice ◽  
Lymphocytic Leukemia ◽  
Western World ◽  
High Prevalence ◽  
Adult Leukemia ◽  
High Chance

Monoclonal B-cell lymphocytosis (MBL) is a recently described medical condition that displays biological similarities to the most common subtype of adult leukemia in the Western world, i.e. chronic lymphocytic leukemia (CLL). Diagnostic criteria have been published with the aim of differentiating between these two entities. The overall prevalence of MBL is at least 100 times higher than that of CLL, which indirectly suggests that MBL is not necessarily a pre-leukemic condition, although in some circumstances, CLL cases can really be preceded by MBL. In view of this high prevalence rate, general clinicians and even non-hematological specialists have a high chance of being faced with individuals with MBL in their routine clinical practice. MBL is classified as "clinical MBL", "population-screening MBL" and "atypical MBL" and the clinical management of affected individuals depends greatly on this differentiation. The present review provides a guide to diagnosing and following up MBL patients.

Sign in / Sign up

Export Citation Format

Share Document